Monte Rosa Therapeutics (NASDAQ:GLUE) Lowered to “Strong Sell” Rating by Zacks Research

Monte Rosa Therapeutics (NASDAQ:GLUE) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Monday,Zacks.com reports.

Several other equities research analysts have also issued reports on GLUE. Wells Fargo & Company dropped their price target on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, March 18th. Weiss Ratings raised Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, May 11th. JPMorgan Chase & Co. upped their target price on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Wall Street Zen cut shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Finally, Guggenheim lifted their price target on shares of Monte Rosa Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Seven analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $33.33.

Monte Rosa Therapeutics Trading Up 4.9%

Shares of GLUE stock opened at $24.40 on Monday. The firm’s 50 day moving average is $19.52 and its 200 day moving average is $18.98. The stock has a market capitalization of $2.06 billion, a P/E ratio of -16.49 and a beta of 1.56. Monte Rosa Therapeutics has a 12 month low of $4.12 and a 12 month high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%.The company had revenue of $4.21 million during the quarter, compared to analysts’ expectations of $10.95 million. On average, equities analysts predict that Monte Rosa Therapeutics will post -1.23 EPS for the current year.

Insider Transactions at Monte Rosa Therapeutics

In related news, COO Jennifer Champoux sold 2,176 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $19.00, for a total value of $41,344.00. Following the sale, the chief operating officer directly owned 62,371 shares of the company’s stock, valued at $1,185,049. This trade represents a 3.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Sharon Townson sold 6,000 shares of the business’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $23.31, for a total value of $139,860.00. Following the transaction, the insider owned 67,845 shares in the company, valued at approximately $1,581,466.95. This represents a 8.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 87,623 shares of company stock valued at $1,871,979. Company insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Monte Rosa Therapeutics

Hedge funds have recently made changes to their positions in the business. Nisa Investment Advisors LLC lifted its stake in Monte Rosa Therapeutics by 16.7% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock worth $49,000 after acquiring an additional 451 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Monte Rosa Therapeutics by 32.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock worth $50,000 after purchasing an additional 776 shares during the period. ProShare Advisors LLC boosted its stake in shares of Monte Rosa Therapeutics by 11.8% during the 4th quarter. ProShare Advisors LLC now owns 11,374 shares of the company’s stock valued at $178,000 after purchasing an additional 1,199 shares in the last quarter. MetLife Investment Management LLC raised its stake in Monte Rosa Therapeutics by 7.5% in the fourth quarter. MetLife Investment Management LLC now owns 26,187 shares of the company’s stock worth $411,000 after buying an additional 1,831 shares in the last quarter. Finally, GAMMA Investing LLC purchased a new stake in Monte Rosa Therapeutics in the fourth quarter worth about $30,000. 79.96% of the stock is owned by hedge funds and other institutional investors.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.